Potential New Drug Target for Protection against Certain Neurodegenerative Diseases

Hypermethylation - the epigenetic ability to turn down or turn off a bad gene implicated in 10 to 30 percent of patients with Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Degeneration (FTD) - serves as a protective barrier inhibiting the development of these diseases, researchers have found. Their work may suggest a neuroprotective target for drug discovery efforts.